Literature DB >> 2539321

Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft.

S A Yousem1, P Randhawa, J Locker, I L Paradis, J A Dauber, B P Griffith, M A Nalesnik.   

Abstract

Heart-lung transplant recipients are predisposed to acute rejection episodes, bronchiolitis obliterans, and opportunistic infections. In 9.4% of recipients at the University of Pittsburgh, a posttransplant lymphoproliferative disorder (PTLD) developed, and in 60% of cases, it presented in the allografted lungs and was associated with primary infection by Epstein-Barr virus (EBV). The PTLD is histologically indistinguishable from a primary pulmonary lymphoma and consists of a mixed population of large lymphoid cells, immunoblasts, and plasma cells. Two cases of PTLD were monoclonal with immunohistochemical and Southern blot analysis. Despite this, there was clinical recovery with reduced immunosuppression and acyclovir. We discuss the role of EBV in the development of PTLD and the pathogenesis of primary presentation in the allograft.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539321     DOI: 10.1016/0046-8177(89)90046-4

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.

Authors:  Khalid Mumtaz; Nabiha Faisal; Max Marquez; Alicia Healey; Leslie B Lilly; Eberhard L Renner
Journal:  Can J Gastroenterol Hepatol       Date:  2015-06-15

2.  Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart-lung transplantation.

Authors:  J J Egan; P S Hasleton; N Yonan; A N Rahman; A K Deiraniya; K B Carroll; A A Woodcock
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

3.  Tissue polypeptide specific antigen for the detection of lymphoproliferative diseases induced by cyclosporin.

Authors:  M Vogl; A Griesmacher; M Grimm; W Klepetko; M M Müller
Journal:  J Clin Pathol       Date:  1995-11       Impact factor: 3.411

4.  Interleukin-6 production in posttransplant lymphoproliferative disease.

Authors:  G Tosato; K Jones; M K Breinig; H P McWilliams; J L McKnight
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

5.  Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.

Authors:  A Chadburn; N Suciu-Foca; E Cesarman; E Reed; R E Michler; D M Knowles
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

6.  Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML.

Authors:  Bita Fakhri; Mark Fiala; Michael Slade; Peter Westervelt; Armin Ghobadi
Journal:  Case Rep Hematol       Date:  2017-02-20

7.  Remission of late-onset post-heart transplantation lymphoproliferative disorder following treatment with rituximab and modified mini-CHOP chemotherapy: A case report.

Authors:  Qiang Huang; Tianxin Yang; Xing Jin; Xuming Ni; Haiyan Qi; Zhikun Yan
Journal:  Exp Ther Med       Date:  2016-05-05       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.